Seminars in Vascular Surgery
Volume 19, Issue 2 , Pages 102-108 , June 2006

Drug-Eluting Stents for Infrainguinal Occlusive Disease: Progress and Challenges

  • Gunnar Tepe, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Gunnar Tepe, Department of Diagnostic Radiology, University of Tuebingen, Hoppe-Seyler-Str. 3, D-72076 Tuebingen, Germany.

References 

  1. Farb A , Weber DK , Kolodgie FD , Burke AP , Virmani R . Morphological predictors of restenosis after coronary stenting in humans . Circulation . 2002;105:2974–2980
  2. Morice MC , Serruys PW , Sousa JE , et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization . N Engl J Med . 2002;346:1773–1780
  3. Ruygrok PN , Melkert R , Morel MA , et al.  Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators . J Am Coll Cardiol . 1999;34:1507–1511
  4. Stone GW , Ellis SG , Cox DA , et al.  One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent (The TAXUS-IV trial) . Circulation . 2004;109:1942–1947
  5. Chieffo A , Colombo A . Polymer-based paclitaxel-eluting coronary stents. Clinical results in de novo lesions . Herz . 2004;29:147–151
  6. Duda SH , Pusich B , Richter G , et al.  Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery diseases (Six-month results) . Circulation . 2002;106:1505–1509
  7. Duda SH , Poerner TC , Wiesinger B , et al.  Drug-eluting stentss (Potential applications for peripheral arterial occlusive disease) . J Vasc Interv Radiol . 2003;14:291–301
  8. Virmani R , Farb A . Pathology of in-stent restenosis . Curr Opin Lipidol . 1999;10:499–506
  9. Virmani R , Liistro F , Stankovic G , et al.  Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans . Circulation . 2002;106:2649–2651
  10. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC) . Eur J Vasc Endovasc Surg . 2000;19(suppl A): Si-xxviii, S1-250
  11. Cheng SW , Ting AC , Wong J . Endovascular stenting of superficial femoral artery stenosis and occlusionss (Results and risk factor analysis) . Cardiovasc Surg . 2001;9:133–140
  12. Murray RR , Hewes RC , White RI , et al.  Long-segment femoropopliteal stenosess (Is angioplasty a boon or a bust?) . Radiology . 1987;162:473–476
  13. Riessen R , Oberhoff M , Karsch KR . Konzepte zur lokalen therapie der restenose. [Concepts for local therapy of restenosis] . Z Kardiol . 1996;85(suppl 1):87–98
  14. Radke PW , vom-Dahl J , Klues HG . Stent-restenoses (Therapiekonzepte und Moglichkeiten der Pravention) . Med Klin . 1999;94:88–92
  15. Phillips-Hughes J , Kandarpa K . Restenosiss (Pathophysiology and preventive strategies) . J Vasc Interv Radiol . 1996;7:321–333
  16. Teirstein PS , Massullo V , Jani S , et al.  A subgroup analysis of the Scripps Coronary Radiation to Inhibit Proliferation Poststenting Trial . Int J Radiat Oncol Biol Phys . 1998;42:1097–1104
  17. Serruys PW , Kay IP . I like the candy, I hate the wrappers (The (32)P radioactive stent) . Circulation . 2000;101:3–7
  18. Tepe G , Dinkelborg LM , Brehme U , et al.  Prophylaxis of restenosis with Re-186 labeled stents in a rabbit model . Circulation . 2001;104:480–485
  19. Virmani R , Farb A , Carter AJ , Jones RM . Pathology of radiation-induced coronary artery disease in human and pig . Cardiovasc Radiat Med . 1999;1:98–101
  20. Waksman R . Intracoronary brachytherapy in the Cath Lab. Physics dosimetry, technology and safety considerations . Herz . 1998;23:401–406
  21. Waksman R , Ajani AE , White RL , et al.  Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosiss (Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS)) . Circulation . 2001;103:2332–2335
  22. MERCATOR Study Group . Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group . Circulation . 1992;86:100–110
  23. Tepe G , Duda SH , Kalinowski M , et al.  Local intra-arterial drug delivery for prevention of restenosis. Comparison of the efficiency of delivery of different radiopharmaceuticals through a porous catheter . Invest Radiol . 2001;36:245–249
  24. Tepe G , Duda SH , Hanke H , et al.  Covered stents for prevention of restenosis. Experimental and clinical results with different stent designs . Invest Radiol . 1996;31:223–229
  25. Babapulle MN , Eisenberg MJ . Coated stents for the prevention of restenosiss (Part II) . Circulation . 2002;106:2859–2866
  26. Fattori R , Piva T . Drug-eluting stents in vascular intervention . Lancet . 2003;361:247–249
  27. Virmani R , Farb A , Kolodgie FD . Histopathologic alterations after endovascular radiation and antiproliferative stentss (Similarities and differences) . Herz . 2002;27:1–6
  28. Silber S . Paclitaxel-eluting stents: Are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients . J Interv Cardiol . 2003;16:485–490
  29. Toutouzas K , Di Mario C , Falotico R , et al.  Sirolimus-eluting stentss (A review of experimental and clinical findings) . Z Kardiol . 2002;91(suppl 3):49–57
  30. Sousa JE , Costa MA , Sousa AG , et al.  Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries . Circulation . 2003;107:381–383
  31. Axel DI , Kunert W , Goggelmann C , et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery . Circulation . 1997;96:636–645
  32. Grube E , Bullesfeld L . Initial experience with paclitaxel-coated stents . J Interv Cardiol . 2002;15:471–475
  33. Grube E , Silber S , Hauptmann KE , et al.  TAXUS Is (Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions) . Circulation . 2003;107:38–42
  34. Colombo A , Drzewiecki J , Banning A , et al.  Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions . Circulation . 2003;108:788–794
  35. Gallo R , Padurean A , Jayaraman T , et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle . Circulation . 1999;99:2164–2170
  36. Morice MC , Serruys PW , Sousa JE , et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization . N Engl J Med . 2002;346:1773–1780
  37. Moussa I , Leon MB , Baim DS , et al.  Impact of sirolimus-eluting stents on outcome in diabetic patientss (A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy) . Circulation . 2004;109:2273–2278
  38. Holmes DR , Leon MB , Moses JW , et al.  Analysis of 1-year clinical outcomes in the SIRIUS trials (A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis) . Circulation . 2004;109:634–640
  39. Sousa JE , Costa MA , Abizaid A , et al.  Sirolimus-eluting stent for the treatment of in-stent restenosiss (A quantitative coronary angiography and three-dimensional intravascular ultrasound study) . Circulation . 2003;107:24–27
  40. Schofer J , Schluter M , Gershlick AH , et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteriess (Double-blind, randomised controlled trial (E-SIRIUS)) . Lancet . 2003;362:1093–1099
  41. Duda SH , Bosiers M , Lammer J , et al.  Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery diseases (The SIROCCO II trial) . J Vasc Interv Radiol . 2005;16:331–338
  42. Scheinert D , Scheinert S , Sax J , et al.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting . J Am Coll Cardiol . 2005;45:312–315
  43. Do DD , Mahler F . Fortschritte in der endovaskularen Therapie peripherer Arterien. [Progress in endovascular therapy of peripheral arteries] . Schweiz Rundsch Med Prax . 2000;89:1105–1113
  44. Zeller T , Rastan A , Schwarzwalder U , et al.  Percutaneous peripheral atherectomy of femoropopliteal stenoses using a new-generation devices (Six-month results from a single-center experience) . J Endovasc Ther . 2004;11:676–685
  45. Grenacher L , Saam T , Geier A , et al.  [PTA versus Palmaz stent placement in femoropopliteal artery stenosess (Results of a multicenter prospective randomized study (REFSA)]) . Rofo . 2004;176:1302–1310
  46. Sabeti S , Mlekusch W , Amighi J , Minar E , Schillinger M . Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries . J Endovasc Ther . 2005;12:6–12
  47. Atar E , Siegel Y , Avrahami R , Bartal G , Bachar GN , Belenky A . Balloon angioplasty of popliteal and crural arteries in elderly with critical chronic limb ischemia . Eur J Radiol . 2005;53:287–292
  48. Soder HK , Manninen HI , Jaakkola P , et al.  Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemias (Angiographic and clinical results) . J Vasc Interv Radiol . 2000;11:1021–1031
  49. Feiring AJ , Wesolowski AA , Lade S . Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudications (Early and one-year outcomes) . J Am Coll Cardiol . 2004;44:2307–2314

PII: S0895-7967(06)00019-6

doi: 10.1053/j.semvascsurg.2006.03.007

Seminars in Vascular Surgery
Volume 19, Issue 2 , Pages 102-108 , June 2006

Article Tools

* Image Usage & Resolution